Evidence map›Paper›PMID 41021038›Full record

ArticleUrolithiasis2025

Global, regional, and National lifetime risks of developing and dying from urolithiasis: a population-based systematic analysis from 1990 to 2021.

Yongming Chen, Wenshuang Li, Yuhao Li, Huimin Hou, Lingfeng Li, Miao Wang, Shengfeng Wang, Ming Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yongming Chen *Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Wenshuang Li *Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, 510630, People's Republic Of China.
Yuhao Li *Department of Epidemiology and Biostatistics, School of Public Health, Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, 100191, China.
Huimin HouDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Lingfeng LiDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Miao WangDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Shengfeng WangDepartment of Epidemiology and Biostatistics, School of Public Health, Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, 100191, China. wangshengfeng@bjmu.edu.cn.
Ming LiuDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. liumingbjh@126.com.

Funding

National High Level Hospital Clinical Research Funding BJ-2022-143National Key Research and Development Program of China 2022YFC3602900
6 · The paper itself

Abstract

Urolithiasis is a common condition worldwide, marked by significant variations in lifetime risk across different regions, genders, and socioeconomic backgrounds. Understanding these disparities is crucial for developing effective public health strategies. This study aims to analyze these risks from 1990 to 2021 and project future trends in the incidence and mortality of urolithiasis. Data were obtained from the Global Burden of Disease (GBD) 2021 study, which provides comprehensive estimates on urolithiasis incidence, prevalence, and mortality across various demographics. Analyses were stratified by gender, age, Sociodemographic Index (SDI), and geographic regions, and included assessments of temporal trends and concentration indices (CIs). Additionally, AutoRegressive Integrated Moving Average (ARIMA) models were employed to project future trends regarding the lifetime risk of developing urolithiasis.The global lifetime risk of developing urolithiasis in 2021 was estimated at 62.95%, with the highest risks observed in Eastern Europe (89.20%), Southern Latin America (80.34%), and Central Asia (75.75%). Men exhibited a higher risk than women (70.40% vs. 50.34%). The global mortality risk from urolithiasis remained low at 0.03%, with the highest rates found in High-income Asia Pacific (0.07%) and Eastern Europe (0.06%). Notably, the lifetime risk of developing urolithiasis declined with advancing age, particularly after 40. ARIMA projections suggest a moderate increase in lifetime risk, potentially reaching nearly 70% by 2050, especially among females. Urolithiasis demonstrates significant global and regional disparities influenced by socioeconomic, environmental, and demographic factors. Comprehensive strategies that address these disparities will be essential for enhancing public health outcomes and reducing the incidence of urolithiasis worldwide.

Indexed as

UrolithiasisAdolescentAdultAgedFemaleGlobal Burden of DiseaseGlobal HealthHumansIncidenceMaleMiddle AgedPrevalenceRisk AssessmentRisk FactorsSocioeconomic FactorsYoung AdultGlobal burden of diseaseLifetime riskPublic health strategiesUrolithiasis

Identifiers

PMID41021038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.